- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Regeneron gains rights to Hansoh's GLP-1/GIP receptor agonist in deal worth $2bn | ||
| Mi | Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma | ||
| Mi | Dermaliq and DEBRA partner to advance epidermolysis bullosa drug delivery | ||
| Mi | Inizio Evoke appoints Matthew Hoelzle as chief medical officer | ||
| Mi | Building inclusive clinical trials through policy reform | ||
| Mi | Turning cold facts into compassionate conversations: the power of patient-centricity in medical education | ||
| Di | BMS and BioNTech partner on solid tumour candidate in deal worth over $11bn | ||
| Di | AstraZeneca's Forxiga recommended by NICE for wider chronic kidney disease use | ||
| Di | Roche/Jazz Pharmaceuticals share positive phase 3 results for lung cancer combination therapy | ||
| Di | Focusing on the patient voice to improve outcomes | ||
| Di | How can we achieve the right balance of HCP engagements in medcomms? | ||
| Mo | Pfizer shares 'unprecedented' survival results for Braftovi in colorectal cancer | ||
| Mo | Sanofi to expand immunology capabilities with $9.5bn Blueprint Medicines acquisition | ||
| Mo | Eli Lilly's Omvoh recommended by NICE to treat Crohn's disease in adults | ||
| Mo | Between luck and leadership: success because of, not despite, strategy | ||
| Mo | The evolution of AI in clinical trials: from promise to practice | ||
| Fr | Roche shares positive 96-week results for multiple sclerosis candidate fenebrutinib | ||
| Fr | AstraZeneca receives CHMP recommendation for Imfinzi regimen in bladder cancer | ||
| Fr | Sanofi and Stagecoach Performing Arts partner to highlight impact of autoimmune type 1 diabetes | ||
| Fr | UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis | ||
| Fr | In an era of deep uncertainty, life sciences companies require more than agile communications | ||
| Fr | Can we create a world where health is sustainable? | ||
| 29.05. | Biogen and City Therapeutics to develop RNAi therapies in deal worth over $1bn | ||
| 29.05. | Sanofi gains access to Alzheimer's candidate through $470m Vigil acquisition | ||
| 29.05. | The future of customer engagement in biopharma |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .